{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:25:37Z","timestamp":1790270737338,"version":"4.1.0"},"reference-count":172,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012353","name":"Deutschen Konsortium f\u00fcr Translationale Krebsforschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012353","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005722","name":"Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005722","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009401","name":"LMU Faculty of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009401","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.ejca.2023.01.030","type":"journal-article","created":{"date-parts":[[2023,2,18]],"date-time":"2023-02-18T02:18:01Z","timestamp":1676686681000},"page":"151-171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Survival and immunotoxicities in association with sex-specific body composition patterns of cancer patients undergoing immune-checkpoint inhibitor therapy \u2013 A systematic review and meta-analysis"],"prefix":"10.1016","volume":"184","author":[{"given":"Paul","family":"Trinkner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"G\u00fcnther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Monsef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Kerschbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"von Bergwelt-Baildon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Cordas dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5706-8258","authenticated-orcid":false,"given":"Sebastian","family":"Theurich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2023.01.030_bib1","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.01.030_bib2","first-page":"1014","article-title":"[Immuncheckpoint Inhibitors: Current Indications and Possible Future Concepts]","volume":"143","author":"Schlaak","year":"2018","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1016\/j.ejca.2023.01.030_bib3","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Anna Oncol"},{"key":"10.1016\/j.ejca.2023.01.030_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102134","article-title":"Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors-a systematic review and meta-analysis","volume":"92","author":"Hussaini","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2023.01.030_bib5","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1080\/01635581.2017.1367947","article-title":"Clinical Value of Nutritional Status in Cancer: What is its Impact and how it Affects Disease Progression and Prognosis?","volume":"69","author":"Mantzorou","year":"2017","journal-title":"Nutr Cancer"},{"key":"10.1016\/j.ejca.2023.01.030_bib6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1475-2891-11-27","article-title":"Role of nutritional status in predicting quality of life outcomes in cancer \u2013 a systematic review of the epidemiological literature","volume":"11","author":"Lis","year":"2012","journal-title":"Nutr J"},{"key":"10.1016\/j.ejca.2023.01.030_bib7","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-nutr-071811-150713","article-title":"Obesity in cancer survival","volume":"32","author":"Parekh","year":"2012","journal-title":"Ann Rev Nutr"},{"key":"10.1016\/j.ejca.2023.01.030_bib8","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nrclinonc.2013.120","article-title":"Clinical management of obese patients with cancer","volume":"10","author":"Tao","year":"2013","journal-title":"Nat Rev. Clin Oncol"},{"key":"10.1016\/j.ejca.2023.01.030_bib9","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0140-6736(14)60892-8","article-title":"Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5\u00b724 million UK adults","volume":"384","author":"Bhaskaran","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2023.01.030_bib10","doi-asserted-by":"crossref","first-page":"7480","DOI":"10.1038\/srep07480","article-title":"Body mass index and risk of breast cancer: a nonlinear dose-response meta-analysis of prospective studies","volume":"4","author":"Xia","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejca.2023.01.030_bib11","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1200\/JCO.2007.14.4527","article-title":"Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer","volume":"26","author":"Litton","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.01.030_bib12","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1093\/annonc\/mdu042","article-title":"Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies","volume":"25","author":"Chan","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2023.01.030_bib13","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1200\/JCO.2011.39.9436","article-title":"Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline","volume":"30","author":"Griggs","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.01.030_bib14","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.1996.14.11.3000","article-title":"Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541","volume":"14","author":"Rosner","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.01.030_bib15","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nrclinonc.2013.108","article-title":"Chemotherapy dosing in overweight and obese patients with cancer","volume":"10","author":"Lyman","year":"2013","journal-title":"Nat Rev Cli Oncol"},{"key":"10.1016\/j.ejca.2023.01.030_bib16","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ejca.2015.12.030","article-title":"Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic review","volume":"57","author":"Shachar","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.01.030_bib17","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.coph.2015.04.003","article-title":"Cachexia and sarcopenia: mechanisms and potential targets for intervention","volume":"22","author":"Argil\u00e9s","year":"2015","journal-title":"Cur Opinion Pharmacol"},{"key":"10.1016\/j.ejca.2023.01.030_bib18","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1159\/000356760","article-title":"Sarcopenia, Cachexia and Aging: Diagnosis, Mechanisms and Therapeutic Options - A Mini-Review","volume":"60","author":"Ali","year":"2014","journal-title":"Gerontology"},{"key":"10.1016\/j.ejca.2023.01.030_bib19","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1470-2045(08)70153-0","article-title":"Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study","volume":"9","author":"Prado","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.01.030_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.nut.2022.111704","article-title":"Prevalence and prognostic value of sarcopenic obesity in patients with cancer: A systematic review and meta-analysis","volume":"101","author":"Gao","year":"2022","journal-title":"Nutr (Burbank, Los Angeles County, Calif)"},{"key":"10.1016\/j.ejca.2023.01.030_bib21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.clnu.2016.07.015","article-title":"ESPEN guidelines on nutrition in cancer patients","volume":"36","author":"Arends","year":"2017","journal-title":"Clin Nutr (Edinburgh, Scotland)"},{"key":"10.1016\/j.ejca.2023.01.030_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107923","article-title":"Exploiting the obesity-associated immune microenvironment for cancer therapeutics","volume":"229","author":"Desharnais","year":"2022","journal-title":"Pharmacol & Ther"},{"key":"10.1016\/j.ejca.2023.01.030_bib23","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cmet.2017.09.015","article-title":"Molecular Mechanisms Linking Exercise to Cancer Prevention and Treatment","volume":"27","author":"Hojman","year":"2018","journal-title":"Cell Metab"},{"key":"10.1016\/j.ejca.2023.01.030_bib24","unstructured":"Collaboration TC. Review Manager (RevMan). 5.4 ed2020."},{"key":"10.1016\/j.ejca.2023.01.030_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"10.1016\/j.ejca.2023.01.030_bib26","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/cam4.2807","article-title":"Predictive factors for progression-free survival in non-small cell lung cancer patients receiving nivolumab based on performance status","volume":"9","author":"Adachi","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2023.01.030_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.699668","article-title":"Predictive value of skeletal muscle mass in recurrent\/metastatic head and neck squamous cell carcinoma patients treated with immune checkpoint inhibitors","volume":"11","author":"Arribas","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2023.01.030_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.832419","article-title":"Efficacy of Immune Checkpoint Inhibitors in Patients With EGFR Mutated NSCLC and Potential Risk Factors Associated With Prognosis: A Single Institution Experience","volume":"13","author":"Bai","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejca.2023.01.030_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108985","article-title":"Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study","volume":"110","author":"Banna","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.ejca.2023.01.030_bib30","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.3390\/cancers14092293","article-title":"Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study","volume":"14","author":"Basso","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2023.01.030_bib31","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3233\/KCA-180047","article-title":"Targeted therapy and immunotherapy: effect of body mass index on clinical outcomes in patients diagnosed with metastatic renal cell carcinoma","volume":"3","author":"Bergerot","year":"2019","journal-title":"Kidney Cancer"},{"key":"10.1016\/j.ejca.2023.01.030_bib32","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001403","article-title":"Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression \u2265 50%: a multicenter study with external validation","volume":"8","author":"Cortellini","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2023.01.030_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2020.109340","article-title":"Impact of CT-based body composition parameters at baseline, their early changes and response in metastatic cancer patients treated with immune checkpoint inhibitors","volume":"133","author":"Cromb\u00e9","year":"2020","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.ejca.2023.01.030_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12051257","volume":"12","author":"Dimitrakopoulos","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejca.2023.01.030_bib35","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.3390\/curroncol28050357","article-title":"Effectiveness and Safety of First-Line Pembrolizumab in Older Adults with PD-L1 Positive Non-Small Cell Lung Cancer: A Retrospective Cohort Study of the Alberta Immunotherapy Database","volume":"28","author":"Grosjean","year":"2021","journal-title":"Cur Oncol"},{"key":"10.1016\/j.ejca.2023.01.030_bib36","doi-asserted-by":"crossref","DOI":"10.21037\/atm-21-3376","article-title":"Blood alkaline phosphatase predicts prognosis of patients with advanced HER2-negative gastric cancer receiving immunotherapy","volume":"9","author":"Hu","year":"2021","journal-title":"Ann Trans Med"},{"key":"10.1016\/j.ejca.2023.01.030_bib37","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/ijc.33822","article-title":"Risk factors for immune-related adverse events from anti-PD-1 or anti-PD-L1 treatment in an Asian cohort of nonsmall cell lung cancer patients","volume":"150","author":"Huang","year":"2022","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2023.01.030_bib38","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.lungcan.2019.11.011","article-title":"The impact of body mass index on the efficacy of anti-PD-1\/PD-L1 antibodies in patients with non-small cell lung cancer","volume":"139","author":"Ichihara","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2023.01.030_bib39","doi-asserted-by":"crossref","first-page":"6971","DOI":"10.1002\/cam4.4220","article-title":"Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer","volume":"10","author":"Imai","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2023.01.030_bib40","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1111\/1759-7714.14417","article-title":"Pretreatment body mass index predicts survival among patients administered nivolumab monotherapy for pretreated non-small cell lung cancer","volume":"13","author":"Imai","year":"2022","journal-title":"Thoracic Cancer"},{"key":"10.1016\/j.ejca.2023.01.030_bib41","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s10147-018-1345-9","article-title":"Predicting marker for early progression in unresectable melanoma treated with nivolumab","volume":"24","author":"Kondo","year":"2019","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.01.030_bib42","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1530\/EJE-20-1362","article-title":"Metabolic disease and adverse events from immune checkpoint inhibitors","volume":"184","author":"Leiter","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ejca.2023.01.030_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-022-09744-5","article-title":"Body mass index and serum markers associated with progression-free survival in lung cancer patients treated with immune checkpoint inhibitors","volume":"22","author":"Liu","year":"2022","journal-title":"BMC cancer"},{"key":"10.1016\/j.ejca.2023.01.030_bib44","series-title":"Examining the impact of body mass index on overall survival in vulvar, vaginal and other mucosal melanomas: a retrospective cohort study","author":"Naderi-Azad","year":"2020"},{"key":"10.1016\/j.ejca.2023.01.030_bib45","doi-asserted-by":"crossref","first-page":"510","DOI":"10.3390\/metabo10120510","article-title":"Possible influence of weight gain and creatinine levels in predicting response to nivolumab: a multicenter analysis","volume":"10","author":"Nitipir","year":"2020","journal-title":"Metabolites"},{"key":"10.1016\/j.ejca.2023.01.030_bib46","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1016\/j.amjcard.2020.02.016","article-title":"Cardiovascular Health and Outcomes in Cancer Patients Receiving Immune Checkpoint Inhibitors","volume":"125","author":"Oren","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejca.2023.01.030_bib47","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1580128","article-title":"Sub-cutaneous Fat Mass measured on multislice computed tomography of pretreatment PET\/CT is a prognostic factor of stage IV non-small cell lung cancer treated by nivolumab","volume":"8","author":"Popinat","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ejca.2023.01.030_bib48","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/COC.0000000000000828","article-title":"Prognostic Factors of Second-line Immune Checkpoint Inhibitors in Patients With Advanced-stage Non\u2013Small Cell Lung Cancer: A Multicenter, Retrospective Study","volume":"44","author":"Roh","year":"2021","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.01.030_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0252537","article-title":"Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1\/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study","volume":"16","author":"Rounis","year":"2021","journal-title":"PloS one"},{"key":"10.1016\/j.ejca.2023.01.030_bib50","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.21037\/tlcr-21-460","article-title":"Cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1\/PD-L1 inhibitors: results from a prospective, observational study","volume":"10","author":"Rounis","year":"2021","journal-title":"Trans Lung Cancer Res"},{"key":"10.1016\/j.ejca.2023.01.030_bib51","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.lungcan.2020.04.034","article-title":"Serum markers associated with treatment response and survival in non-small cell lung cancer patients treated with anti-PD-1 therapy","volume":"145","author":"Takada","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2023.01.030_bib52","first-page":"5857","article-title":"Predictive factors for poor progression-free survival in patients with non-small cell lung cancer treated with nivolumab","volume":"37","author":"Taniguchi","year":"2017","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ejca.2023.01.030_bib53","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nm.1964","article-title":"CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity","volume":"15","author":"Nishimura","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2023.01.030_bib54","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1007\/s00405-020-05945-5","article-title":"Predicting the treatment outcome of nivolumab in recurrent or metastatic head and neck squamous cell carcinoma: prognostic value of combined performance status and modified Glasgow prognostic score","volume":"277","author":"Ueki","year":"2020","journal-title":"Eur Archive Oto-Rhino-Laryngol"},{"key":"10.1016\/j.ejca.2023.01.030_bib55","first-page":"100","article-title":"The effect of pretreatment BMI on the prognosis and serum immune cells in advanced LSCC patients who received ICI therapy","author":"Wang","year":"2021","journal-title":"Medicine"},{"key":"10.1016\/j.ejca.2023.01.030_bib56","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41591-018-0221-5","article-title":"Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade","volume":"25","author":"Wang","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2023.01.030_bib57","doi-asserted-by":"crossref","first-page":"9015","DOI":"10.21037\/apm-21-1827","article-title":"Programmed cell death protein-1 inhibitors in the treatment of digestive system tumors in Chinese population: an observational study of effectiveness and safety","volume":"10","author":"Yang","year":"2021","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.ejca.2023.01.030_bib58","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002349","article-title":"Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors","volume":"9","author":"Ahmed","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2023.01.030_bib59","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/COC.0000000000000787","article-title":"Impact of sarcopenia, BMI, and inflammatory biomarkers on survival in advanced hepatocellular carcinoma treated with anti-PD-1 antibody","volume":"44","author":"Akce","year":"2021","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.01.030_bib60","first-page":"11","article-title":"Immune-related adverse events in PD-1 treated melanoma and impact upon anti-tumor efficacy: A real world analysis","author":"Bastacky","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2023.01.030_bib61","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000725","article-title":"Obesity diminishes response to PD-1-based immunotherapies in renal cancer","volume":"8","author":"Boi","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2023.01.030_bib62","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.3390\/cancers13092200","article-title":"Association between Body Mass Index and Survival Outcome in Metastatic Cancer Patients Treated by Immunotherapy: Analysis of a French Retrospective Cohort","volume":"13","author":"Collet","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2023.01.030_bib63","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1080\/1120009X.2020.1849488","article-title":"Prognostic factors and effect on survival of immune-related adverse events in patients with non-small-cell lung cancer treated with immune checkpoint blockage","volume":"33","author":"Conde-Est\u00e9vez","year":"2020","journal-title":"J Chemotherapy"},{"key":"10.1016\/j.ejca.2023.01.030_bib64","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s40425-019-0527-y","article-title":"A multicenter study of body mass index in cancer patients treated with anti-PD-1\/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable","volume":"7","author":"Cortellini","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2023.01.030_bib65","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejca.2019.12.031","volume":"128","author":"Cortellini","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.01.030_bib66","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004374","article-title":"Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations","volume":"10","author":"Cortellini","year":"2022","journal-title":"J Immunotherapy Cancer"},{"key":"10.1016\/j.ejca.2023.01.030_bib67","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/bjc.2016.431","article-title":"The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma","volume":"116","author":"Daly","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2023.01.030_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-021-03134-4","article-title":"Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab","volume":"19","author":"De Filippi","year":"2021","journal-title":"J Transl Med"},{"key":"10.1016\/j.ejca.2023.01.030_bib69","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1158\/1078-0432.CCR-18-3661","article-title":"Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab","volume":"25","author":"De Giorgi","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2023.01.030_bib70","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.annonc.2020.12.012","article-title":"Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data(\u2606)","volume":"32","author":"Di Filippo","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2023.01.030_bib71","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/s40425-019-0699-5","article-title":"The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients","volume":"7","author":"Donnelly","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2023.01.030_bib72","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ejca.2020.12.028","article-title":"Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis","volume":"145","author":"Esposito","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.01.030_bib73","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-50574-6","article-title":"Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab","volume":"9","author":"Eun","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejca.2023.01.030_bib74","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.638312","article-title":"Inflammatory Markers Predict Survival in Patients With Advanced Gastric and Colorectal Cancers Receiving Anti\u2013PD-1 Therapy","volume":"9","author":"Fan","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.ejca.2023.01.030_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100107","article-title":"High body mass index and pre-existing autoimmune disease are associated with an increased risk of immune-related adverse events in cancer patients treated with PD-(L) 1 inhibitors across different solid tumors","volume":"6","author":"G\u00fclave","year":"2021","journal-title":"ESMO open"},{"key":"10.1016\/j.ejca.2023.01.030_bib76","doi-asserted-by":"crossref","first-page":"5772","DOI":"10.3390\/cancers13225772","article-title":"Nutritional Status as a Predictive Biomarker for Immunotherapy Outcomes in Advanced Head and Neck Cancer","volume":"13","author":"Guller","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2023.01.030_bib77","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ejca.2019.11.003","article-title":"The impact of body composition parameters on severe toxicity of nivolumab","volume":"124","author":"Hirsch","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.01.030_bib78","doi-asserted-by":"crossref","first-page":"5245","DOI":"10.21873\/anticanres.14528","article-title":"Higher BMI, But Not Sarcopenia, Is Associated With Pembrolizumab-related Toxicity in Patients With Advanced Melanoma","volume":"40","author":"Hu","year":"2020","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ejca.2023.01.030_bib79","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001674","article-title":"Baseline prognostic nutritional index and changes in pretreatment body mass index associate with immunotherapy response in patients with advanced cancer","volume":"8","author":"Johannet","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2023.01.030_bib80","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9010102","article-title":"Retrospective Efficacy Analysis of Immune Checkpoint Inhibitor Rechallenge in Patients with Non-Small Cell Lung Cancer","volume":"9","author":"Katayama","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.ejca.2023.01.030_bib81","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jamaoncol.2019.5241","article-title":"Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer","volume":"6","author":"Kichenadasse","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2023.01.030_bib82","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1186\/s12967-019-02144-7","article-title":"BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma","volume":"17","author":"Labadie","year":"2019","journal-title":"J Transl Med"},{"key":"10.1016\/j.ejca.2023.01.030_bib83","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/jamaoncol.2021.0019","article-title":"Assessment of immune checkpoint inhibitors and genomic alterations by body mass index in advanced renal cell carcinoma","volume":"7","author":"Lalani","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2023.01.030_bib84","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/cncr.32576","article-title":"Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials","volume":"126","author":"Martini","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2023.01.030_bib85","first-page":"2689","article-title":"Body composition variables as radiographic biomarkers of clinical outcomes in metastatic renal cell carcinoma patients receiving immune checkpoint inhibitors","author":"Martini","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2023.01.030_bib86","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/onco.13922","article-title":"Body composition as an independent predictive and prognostic biomarker in advanced urothelial carcinoma patients treated with immune checkpoint inhibitors","volume":"26","author":"Martini","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2023.01.030_bib87","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S1470-2045(18)30078-0","article-title":"Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis","volume":"19","author":"McQuade","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.01.030_bib88","doi-asserted-by":"crossref","first-page":"9","DOI":"10.14740\/wjon1225","article-title":"Sarcopenia and Visceral Adiposity Did Not Affect Efficacy of Immune-Checkpoint Inhibitor Monotherapy for Pretreated Patients With Advanced Non-Small Cell Lung Cancer","volume":"11","author":"Minami","year":"2020","journal-title":"World J Oncol"},{"key":"10.1016\/j.ejca.2023.01.030_bib89","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s40425-019-0512-5","article-title":"Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition","volume":"7","author":"Naik","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2023.01.030_bib90","doi-asserted-by":"crossref","first-page":"Lmt44","DOI":"10.2217\/lmt-2020-0024","article-title":"Simple parameters to solve a complex issue: predicting response to checkpoint inhibitor therapy in lung cancer","volume":"10","author":"Newman","year":"2020","journal-title":"Lung Cancer Manag"},{"key":"10.1016\/j.ejca.2023.01.030_bib91","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0204729","article-title":"Body mass index may predict the response to ipilimumab in metastatic melanoma: An observational multi-centre study","volume":"13","author":"Richtig","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ejca.2023.01.030_bib92","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1751548","article-title":"Effect of excess weight and immune-related adverse events on the efficacy of cancer immunotherapy with anti-PD-1 antibodies","volume":"9","author":"Rogado","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ejca.2023.01.030_bib93","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001117","article-title":"Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study","volume":"8","author":"Rutkowski","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2023.01.030_bib94","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.585271","article-title":"Systemic immune-inflammation index and changes of neutrophil-lymphocyte ratio as prognostic biomarkers for patients with pancreatic cancer treated with immune checkpoint blockade","volume":"11","author":"Shang","year":"2021","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2023.01.030_bib95","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1093\/ndt\/gfaa137","article-title":"Acute kidney injury in patients treated with anti-programmed death receptor-1 for advanced melanoma: a real-life study in a single-centre cohort","volume":"36","author":"Stein","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ejca.2023.01.030_bib96","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.resinv.2021.11.003","article-title":"Correlation between body mass index and efficacy of anti-PD-1 inhibitor in patients with non-small cell lung cancer","volume":"60","author":"Tateishi","year":"2022","journal-title":"Respir Investig"},{"key":"10.1016\/j.ejca.2023.01.030_bib97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-022-09823-7","article-title":"Use of computed tomography-derived body composition to determine the prognosis of patients with primary liver cancer treated with immune checkpoint inhibitors: a retrospective cohort study","volume":"22","author":"Xiao","year":"2022","journal-title":"BMC cancer"},{"key":"10.1016\/j.ejca.2023.01.030_bib98","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.21037\/tlcr-20-1130","article-title":"Predictive values of genomic variation, tumor mutational burden, and PD-L1 expression in advanced lung squamous cell carcinoma treated with immunotherapy","volume":"9","author":"Xu","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.ejca.2023.01.030_bib99","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1038\/s41416-021-01310-3","article-title":"Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles","volume":"124","author":"Ye","year":"2021","journal-title":"British J Cancer"},{"key":"10.1016\/j.ejca.2023.01.030_bib100","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.0448","article-title":"Outcomes Among Patients With or Without Obesity and With Cancer Following Treatment With Immune Checkpoint Blockade","volume":"5","author":"Yoo","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ejca.2023.01.030_bib101","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000821","article-title":"Impact of body composition on outcomes from anti-PD1 +\/- anti-CTLA-4 treatment in melanoma","volume":"8","author":"Young","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2023.01.030_bib102","first-page":"3135","article-title":"Development and Validation of a Nomogram for Predicting Prognosis to Immune Checkpoint Inhibitors Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer","author":"Zeng","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2023.01.030_bib103","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.3390\/cancers13236109","article-title":"Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis","volume":"13","author":"Zhang","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2023.01.030_bib104","doi-asserted-by":"crossref","DOI":"10.1177\/11795549211004489","article-title":"Real-World outcomes and clinical predictors of immune checkpoint inhibitor monotherapy in advanced lung cancer","volume":"15","author":"Zhang","year":"2021","journal-title":"Clin Med Insight Oncol"},{"key":"10.1016\/j.ejca.2023.01.030_bib105","doi-asserted-by":"crossref","first-page":"316","DOI":"10.21037\/tlcr.2020.04.15","article-title":"Non-alcoholic fatty liver disease is associated with immune checkpoint inhibitor-based treatment response in patients with non-small cell lung cancer with liver metastases","volume":"9","author":"Zhou","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.ejca.2023.01.030_bib106","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1634\/theoncologist.2019-0751","article-title":"Combined effect of sarcopenia and systemic inflammation on survival in patients with advanced stage cancer treated with immunotherapy","volume":"25","author":"Bilen","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2023.01.030_bib107","doi-asserted-by":"crossref","first-page":"7067","DOI":"10.21873\/anticanres.14734","article-title":"Cancer cachexia reduces the efficacy of nivolumab treatment in patients with advanced gastric cancer","volume":"40","author":"Fujii","year":"2020","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ejca.2023.01.030_bib108","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000520833","article-title":"Body Mass Index, Sarcopenia, and Their Variations in Predicting Outcomes for Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma","volume":"100","author":"Herrmann","year":"2022","journal-title":"Oncology"},{"key":"10.1016\/j.ejca.2023.01.030_bib109","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.701668","article-title":"Prognostic Impact of Sarcopenia and Radiotherapy in Patients With Advanced Gastric Cancer Treated With Anti-PD-1 Antibody","volume":"12","author":"Kim","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejca.2023.01.030_bib110","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.3390\/jcm10071361","article-title":"Progressive sarcopenia correlates with poor response and outcome to immune checkpoint inhibitor therapy","volume":"10","author":"Loosen","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.ejca.2023.01.030_bib111","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.3390\/cancers14143551","article-title":"Clinical Usefulness of Monitoring Muscle Volume during Atezolizumab Plus Bevacizumab Therapy in Patients with Unresectable Hepatocellular Carcinoma","volume":"14","author":"Matsumoto","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2023.01.030_bib112","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8040450","article-title":"Association of Sarcopenia with and Efficacy of Anti-PD-1\/PD-L1 Therapy in Non-Small-Cell Lung Cancer","volume":"8","author":"Nishioka","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.ejca.2023.01.030_bib113","doi-asserted-by":"crossref","first-page":"6355","DOI":"10.3390\/cancers13246355","article-title":"Impact of Sarcopenia and Inflammation on Patients with Advanced Non-Small Cell Lung Cancer (NCSCL) Treated with Immune Checkpoint Inhibitors (ICIs): A Prospective Study","volume":"13","author":"Tenuta","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2023.01.030_bib114","first-page":"1","article-title":"Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma","author":"Chen","year":"2022","journal-title":"Eur Radiol"},{"key":"10.1016\/j.ejca.2023.01.030_bib115","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/jcsm.12538","article-title":"Body composition is prognostic and predictive of ipilimumab activity in metastatic melanoma","volume":"11","author":"Chu","year":"2020","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ejca.2023.01.030_bib116","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/s41598-020-58498-2","article-title":"Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1\/PD-L1 checkpoint inhibitors: a multicenter real-life study","volume":"10","author":"Cortellini","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejca.2023.01.030_bib117","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.3390\/diagnostics11122314","article-title":"Deep Learning-Based Body Composition Analysis Predicts Outcome in Melanoma Patients Treated with Immune Checkpoint Inhibitors","volume":"11","author":"Faron","year":"2021","journal-title":"Diagnostics"},{"key":"10.1016\/j.ejca.2023.01.030_bib118","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/CAD.0000000000001279","article-title":"Sarcopenia and the rate of change of the neutrophil\/lymphocyte ratio as predictors of pembrolizumab efficacy in advanced urothelial carcinoma","volume":"33","author":"Fukata","year":"2022","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.ejca.2023.01.030_bib119","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1097\/CAD.0000000000000982","article-title":"Impact of sarcopenia on the efficacy of pembrolizumab in patients with advanced urothelial carcinoma: a preliminary report","volume":"31","author":"Fukushima","year":"2020","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ejca.2023.01.030_bib120","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1080\/0284186X.2021.1978540","article-title":"The impact of sarcopenia on the efficacy and safety of immune checkpoint inhibitors in patients with solid tumours","volume":"60","author":"Haik","year":"2021","journal-title":"Acta Oncologica"},{"key":"10.1016\/j.ejca.2023.01.030_bib121","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s10637-017-0464-x","article-title":"Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients","volume":"35","author":"Heidelberger","year":"2017","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ejca.2023.01.030_bib122","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s10147-020-01833-4","article-title":"Association between skeletal muscle loss and the response to nivolumab immunotherapy in advanced gastric cancer patients","volume":"26","author":"Kano","year":"2021","journal-title":"Int J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2023.01.030_bib123","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s00262-020-02794-3","article-title":"Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab","volume":"70","author":"Kim","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ejca.2023.01.030_bib124","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10120-020-01124-x","article-title":"Prognostic significance of sarcopenia in microsatellite-stable gastric cancer patients treated with programmed death-1 inhibitors","volume":"24","author":"Kim","year":"2021","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.ejca.2023.01.030_bib125","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/cam4.3631","article-title":"Unfavorable impact of decreased muscle quality on the efficacy of immunotherapy for advanced non-small cell lung cancer","volume":"10","author":"Nishioka","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2023.01.030_bib126","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.lungcan.2020.03.003","article-title":"Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors","volume":"143","author":"Roch","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2023.01.030_bib127","article-title":"Clinical Impact of Sarcopenia and Inflammatory\/Nutritional Markers in Patients with Unresectable Metastatic Urothelial Carcinoma Treated with Pembrolizumab","volume":"10","author":"Shimizu","year":"2020","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.ejca.2023.01.030_bib128","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1038\/s41598-019-39120-6","article-title":"Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD-1 inhibitors: A preliminary retrospective study","volume":"9","author":"Shiroyama","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejca.2023.01.030_bib129","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s00432-020-03146-5","article-title":"Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors","volume":"146","author":"Takada","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ejca.2023.01.030_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2022.106018","article-title":"Predictive significance of body composition indices in patients with head and neck squamous cell carcinoma treated with nivolumab: A multicenter retrospective study","volume":"132","author":"Takenaka","year":"2022","journal-title":"Oral Oncology"},{"issue":"7","key":"10.1016\/j.ejca.2023.01.030_bib131","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/jgh3.12777","article-title":"Comparison of the prognostic effect of sarcopenia on atezolizumab plus bevacizumab and lenvatinib therapy in hepatocellular carcinoma patients","volume":"6","author":"Toshida","year":"2022","journal-title":"JGH Open"},{"key":"10.1016\/j.ejca.2023.01.030_bib132","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000019059","article-title":"Skeletal muscle mass predicts the outcome of nivolumab treatment for non-small cell lung cancer","volume":"99","author":"Tsukagoshi","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ejca.2023.01.030_bib133","doi-asserted-by":"crossref","first-page":"415","DOI":"10.4111\/icu.20220028","article-title":"Association between sarcopenia based on psoas muscle index and the response to nivolumab in metastatic renal cell carcinoma: A retrospective study","volume":"63","author":"Ueki","year":"2022","journal-title":"Investigat Clin Urol"},{"key":"10.1016\/j.ejca.2023.01.030_bib134","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1002\/cncr.29472","article-title":"Impact of obesity on outcomes after definitive dose-escalated intensity-modulated radiotherapy for localized prostate cancer","volume":"121","author":"Wang","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2023.01.030_bib135","doi-asserted-by":"crossref","DOI":"10.21037\/atm-21-6578","article-title":"Assessment of sarcopenia as a predictor of poor overall survival for advanced non-small-cell lung cancer patients receiving salvage anti-PD-1 immunotherapy","volume":"9","author":"Wang","year":"2021","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.ejca.2023.01.030_bib136","article-title":"Sarcopenia and systemic inflammation response index predict response to systemic therapy for hepatocellular carcinoma and are associated with immune cells","volume":"12","author":"Zhao","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2023.01.030_bib137","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.3390\/ijms22052628","article-title":"Impact of BMI on Survival Outcomes of Immunotherapy in Solid Tumors: A Systematic Review","volume":"22","author":"Indini","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejca.2023.01.030_bib138","first-page":"1","article-title":"Pretreatment body mass index and clinical outcomes in cancer patients following immune checkpoint inhibitors: a systematic review and meta-analysis","author":"Chen","year":"2020","journal-title":"Cancer Immunol Immunotherapy"},{"key":"10.1016\/j.ejca.2023.01.030_bib139","first-page":"1","article-title":"The predictive value of body mass index on prognosis and adverse events of cancers treated with immunotherapy: a systematic review and meta-analysis","author":"You","year":"2021","journal-title":"Cancer Immunol Immunotherapy"},{"key":"10.1016\/j.ejca.2023.01.030_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.105745","article-title":"The prognostic role of obesity is independent of sex in cancer patients treated with immune checkpoint inhibitors: A pooled analysis of 4090 cancer patients","volume":"74","author":"Xu","year":"2019","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.ejca.2023.01.030_bib141","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S1470-2045(18)30261-4","article-title":"Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis","volume":"19","author":"Conforti","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.01.030_bib142","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2147\/ITT.S126227","article-title":"Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review","volume":"6","author":"Yoest","year":"2017","journal-title":"Immuno Target Therapy"},{"key":"10.1016\/j.ejca.2023.01.030_bib143","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.bulcan.2018.07.005","article-title":"Physiopathological mechanisms of immune-related adverse events induced by anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies in cancer treatment","volume":"105","author":"Passat","year":"2018","journal-title":"Bullet du Cancer"},{"key":"10.1016\/j.ejca.2023.01.030_bib144","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J Immunotherapy cancer"},{"key":"10.1016\/j.ejca.2023.01.030_bib145","first-page":"1","article-title":"Body mass index and immune-related adverse events in patients on immune checkpoint inhibitor therapies: a systematic review and meta-analysis","author":"Guzman-Prado","year":"2020","journal-title":"Cancer Immunol Immunotherapy"},{"key":"10.1016\/j.ejca.2023.01.030_bib146","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Annal Oncol"},{"key":"10.1016\/j.ejca.2023.01.030_bib147","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1467-789X.2009.00623.x","article-title":"Subcutaneous and visceral adipose tissue: structural and functional differences","volume":"11","author":"Ibrahim","year":"2010","journal-title":"Obe Rev"},{"key":"10.1016\/j.ejca.2023.01.030_bib148","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1053\/meta.2001.21693","article-title":"Contributions of total body fat, abdominal subcutaneous adipose tissue compartments, and visceral adipose tissue to the metabolic complications of obesity","volume":"50","author":"Smith","year":"2001","journal-title":"Metab Clin Exp"},{"key":"10.1016\/j.ejca.2023.01.030_bib149","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1093\/ije\/dyu045","article-title":"Body mass index and risk of autoimmune diseases: a study within the Danish National Birth Cohort","volume":"43","author":"Harps\u00f8e","year":"2014","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.ejca.2023.01.030_bib150","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1146\/annurev-physiol-021909-135846","article-title":"Macrophages, inflammation, and insulin resistance","volume":"72","author":"Olefsky","year":"2010","journal-title":"Ann Rev Physiol"},{"key":"10.1016\/j.ejca.2023.01.030_bib151","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016376","article-title":"Visceral adipose inflammation in obesity is associated with critical alterations in tregulatory cell numbers","volume":"6","author":"Deiuliis","year":"2011","journal-title":"PloS one"},{"key":"10.1016\/j.ejca.2023.01.030_bib152","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1210\/jcem-48-4-633","article-title":"Increased estrogen production in obese men","volume":"48","author":"Schneider","year":"1979","journal-title":"J Clin Endocrinol Metabolism"},{"key":"10.1016\/j.ejca.2023.01.030_bib153","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.steroids.2011.10.013","article-title":"Tissue physiology and pathology of aromatase","volume":"77","author":"Stocco","year":"2012","journal-title":"Steroids"},{"key":"10.1016\/j.ejca.2023.01.030_bib154","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/intimm\/dxl151","article-title":"Treg suppressive activity involves estrogen-dependent expression of programmed death-1 (PD-1)","volume":"19","author":"Polanczyk","year":"2007","journal-title":"Int Immunol"},{"key":"10.1016\/j.ejca.2023.01.030_bib155","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cellimm.2015.01.018","article-title":"Estrogen receptors regulate innate immune cells and signaling pathways","volume":"294","author":"Kovats","year":"2015","journal-title":"Cell Immunol"},{"key":"10.1016\/j.ejca.2023.01.030_bib156","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106907","article-title":"Sarcopenia affects clinical efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients: A systematic review and meta-analysis","volume":"88","author":"Wang","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.ejca.2023.01.030_bib157","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/jcsm.12755","article-title":"Predictive impact of sarcopenia in solid cancers treated with immune checkpoint inhibitors: a meta-analysis","volume":"12","author":"Takenaka","year":"2021","journal-title":"J Cachexia, Sarcopenia Muscle"},{"key":"10.1016\/j.ejca.2023.01.030_bib158","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cytogfr.2016.10.003","article-title":"Myokines and adipokines: Involvement in the crosstalk between skeletal muscle and adipose tissue","volume":"33","author":"Li","year":"2017","journal-title":"Cytokine & Growth Factor Rev"},{"key":"10.1016\/j.ejca.2023.01.030_bib159","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1084\/jem.180.4.1395","article-title":"Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor","volume":"180","author":"Carson","year":"1994","journal-title":"J Exp Med"},{"key":"10.1016\/j.ejca.2023.01.030_bib160","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.6536","article-title":"Transpresentation of interleukin-15 by IL-15\/IL-15R\u03b1 mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity","volume":"6","author":"Van den Bergh","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2023.01.030_bib161","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1113\/jphysiol.2007.139618","article-title":"Expression of interleukin-15 in human skeletal muscle\u2013effect of exercise and muscle fibre type composition","volume":"584","author":"Nielsen","year":"2007","journal-title":"J Physiol"},{"key":"10.1016\/j.ejca.2023.01.030_bib162","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.it.2004.09.008","article-title":"Different checkpoints in human NK-cell activation","volume":"25","author":"Moretta","year":"2004","journal-title":"Trends Immunol"},{"key":"10.1016\/j.ejca.2023.01.030_bib163","series-title":"Immune checkpoints on innate lymphoid cells","author":"Chiossone","year":"2017"},{"key":"10.1016\/j.ejca.2023.01.030_bib164","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1084\/jem.191.5.771","article-title":"Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15\u2013deficient mice","volume":"191","author":"Kennedy","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.ejca.2023.01.030_bib165","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1200\/JCO.2014.57.3329","article-title":"Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer","volume":"33","author":"Conlon","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.01.030_bib166","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.exger.2017.12.023","article-title":"Chronic inflammation and sarcopenia: A regenerative cell therapy perspective","volume":"103","author":"Chhetri","year":"2018","journal-title":"Exp Gerontol"},{"key":"10.1016\/j.ejca.2023.01.030_bib167","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx810","article-title":"Sarcopenic obesity: hidden muscle wasting and its impact for survival and complications of cancer therapy","volume":"29","author":"Baracos","year":"2018","journal-title":"Annal Oncol"},{"key":"10.1016\/j.ejca.2023.01.030_bib168","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000521241","article-title":"Definition and Diagnostic Criteria for Sarcopenic Obesity: ESPEN and EASO Consensus Statement","volume":"15","author":"Donini","year":"2022","journal-title":"Obes Fact"},{"key":"10.1016\/j.ejca.2023.01.030_bib169","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejca.2022.10.013","article-title":"Protective effect of obesity on survival in cancers treated with immunotherapy vanishes when controlling for type of cancer, weight loss and reduced skeletal muscle","volume":"178","author":"Antoun","year":"2023","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.ejca.2023.01.030_bib170","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.3324\/haematol.2021.280189","article-title":"Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 CAR-T in advanced B-cell malignancies","volume":"107","author":"Dos Santos","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2023.01.030_bib171","doi-asserted-by":"crossref","first-page":"10405","DOI":"10.1182\/blood-2022-159493","article-title":"Body Composition and Immunonutritional Status Impact Survival Outcomes after CD19 CAR T-Cell Therapy","volume":"140","author":"Rejeski","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2023.01.030_bib172","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.3390\/nu14204280","article-title":"Risk Stratification Based on a Pattern of Immunometabolic Host Factors Is Superior to Body Mass Index-Based Prediction of COVID-19-Associated Respiratory Failure","volume":"14","author":"Cordas dos Santos","year":"2022","journal-title":"Nutrients"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923000795?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923000795?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:40:35Z","timestamp":1760733635000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923000795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":172,"alternative-id":["S0959804923000795"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.01.030","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival and immunotoxicities in association with sex-specific body composition patterns of cancer patients undergoing immune-checkpoint inhibitor therapy \u2013 A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.01.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}